Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06153134
Status:
RECRUITING
Last Update Posted:
2023-12-01
First Post:
2023-11-22
Brief Title:
Curcuma Xanthorriza Roxb 10 Cream for Melasma
Sponsor:
Universitas Padjadjaran
Organization:
Universitas Padjadjaran
Study Overview
Official Title:
Effectiveness of Curcuma Xanthorriza Roxb 10 Cream in Reducing Melasma Area and Severity Index MASI Scores and Improvement of Skin Brightness in Epidermal Type Melasma
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Melasma is an acquired hyperpigmentation disorder with a multifactorial etiology and complex pathogenesis that can significantly diminish the quality of life for affected patients As of now melasma therapy remains challenging due to its high recurrence rate and the common occurrence of treatment-related side effects The use of depigmentation agents is a crucial component in managing melasma Hydroquinone stands as the first-line depigmentation agent for melasma however its use often leads to adverse effects Therefore alternative depigmentation agents are needed Curcuma xanthorriza Roxb a native plant of Indonesia operates by inhibiting the tyrosinase enzyme reducing MITF transcription and inhibiting α-MSH Despite these potential benefits Curcuma xanthorriza Roxb has not been utilized as a depigmentation agent Research on the effectiveness of Curcuma xanthorriza Roxb as a depigmentation agent in melasma treatment has not been conducted Therefore it is essential to conduct research to determine the effectiveness of a 10 Curcuma xanthorrhiza Roxb cream in reducing MASI scores and enhancing skin brightness in epidermal-type melasma
Detailed Description:
Curcuma xanthorrhiza Roxb known locally as temulawak in Indonesia or koneng gede in Sundanese is a member of the Zingiberaceae family and is native to Indonesia Previous research related to Curcuma xanthorriza Roxb and its impact on melanin synthesis was conducted using mushroom tyrosinase by Batubara et al The study found that methanol extract of Curcuma xanthorriza Roxb could decrease tyrosinase enzyme activity with an inhibition concentration 50 IC50 of 027 mgmL
Research conducted by Lee et al on curcumin from another Curcuma species C longa or turmeric demonstrated that curcumin reduced melanin quantity tyrosinase enzyme activity and micropthalmia-associated transcription factor MITF protein In an in-silico study Mustarichie et al reported that the three active compounds in Curcuma xanthorriza Roxb could inhibit both tyrosinase enzyme and α-melanin stimulating hormone α-MSH Xanthorrizol exhibited the most effective interaction with the tyrosinase enzyme while demethoxycurcumin showed the most effective interaction with α-MSH
Up to this point there has been no research on the effectiveness of 10 Curcuma xanthorriza Roxb cream in treating melasma Therefore the researchers are motivated to investigate the efficacy of 10 Curcuma xanthorriza Roxb cream as a depigmentation agent based on the assessment of MASI scores and skin brightness levels in patients with epidermal-type melasma using split-face therapy
Research conducted by Lee et al on curcumin from another Curcuma species C longa or turmeric demonstrated that curcumin reduced melanin quantity tyrosinase enzyme activity and micropthalmia-associated transcription factor MITF protein In an in-silico study Mustarichie et al reported that the three active compounds in Curcuma xanthorriza Roxb could inhibit both tyrosinase enzyme and α-melanin stimulating hormone α-MSH Xanthorrizol exhibited the most effective interaction with the tyrosinase enzyme while demethoxycurcumin showed the most effective interaction with α-MSH
Up to this point there has been no research on the effectiveness of 10 Curcuma xanthorriza Roxb cream in treating melasma Therefore the researchers are motivated to investigate the efficacy of 10 Curcuma xanthorriza Roxb cream as a depigmentation agent based on the assessment of MASI scores and skin brightness levels in patients with epidermal-type melasma using split-face therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None